*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

#

# CHINA HEALTH GROUP INC.

**中國醫療集團有限公司**

(Carrying on business in Hong Kong as “萬全醫療集團”)
(Incorporated in the Cayman Islands with limited liability)(Stock Code: 08225)

**Voluntary announcement**

**New development for the Group's business in the**

**post-COVID-19 era**

Since the State Council released the latest twenty measures for the prevention and control of the epidemic, as well as the latest data released by the World Health Organization on November 15, the cumulative number of confirmed cases of COVID-19 worldwide exceeded 630 million with over 6.59 million deaths.Professor Lu Lin, a member of the WHO Expert Group on Prevention and Control of COVID-19, an academician of the Chinese Academy of Sciences and an expert in psychiatry, clearly pointed out that more than 70 million new patients with depression, 90 million with anxiety and hundreds of millions with insomnia have been added since COVID-19, and such conditions will affect more than 20 years.The above COVID-19 and the new post-COVID-19 situation bring new development opportunities to the company's business.

In response to the epidemic, the Group has been involved in providing real-world clinical research and medical service for the following pharmaceutical products: 1. Anti-COVID-19 drug, Maikexin oral liquid, is a recommended drug component of the 9th edition of the "COVID-19 Pneumonia Treatment Plan" issued by the National Health Commission. 2. One of the main symptoms of COVID-19 is cough, and according to an article by Academician Zhong in The Lancet, Kalinin not only solves cough but also prevents and treats chronic obstructive pulmonary disease. 3.The Group has a variety of drugs to cope with the outbreak of various psychological crises under the epidemic: Quyou has the efficacy of relieving anxiety and helping to treat anxiety, Lefuting treats depression without causing obesity or ED, Caqu treats migraine, Anyun and Maikewei treat anxiety and insomnia without drowsiness. 4.The antihistamines served by the Group are recommended by the Hong Kong and European Society of Hospital Pharmacists as drugs for runny nose symptoms (Mild symptoms of COVID-19).

China Health Group is a leading digital healthcare service provider in the areas of new drug development innovation, research-based specialty clinics and research-based product promotion driven by real-world clinical research and medical big data. The Group focuses on major disease areas such as brain science and allergic reactions, and has built five major specialty brands: Baimin anti-allergic, Xixin spirit, Xien preventing stroke dementia, Yueting quitting Smoking Addiction and Rare Disease ALS.

The Group's management believes that the growth of the COVID-19 outbreak in the Group's medical services sector will bring sustainable good development to the business.Therefore, this announcement is hereby made. Due to the great uncertainty in the market, please consult professionals for careful investment.

By order of the Board

 China Health Group Inc.

 GUO Xia

 Chairman

Hong Kong, 24 November 2022

*As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non-executive Director, being Mr. SU Yi; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling.This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading. This announcement will remain on the “Latest Listed Company Information” page of the GEM website at http://www.hkgem.com for 7 days from the date of its posting. This announcement will also be posted on the Company’s website at http://www.chgi.net.*